v3.26.1
Segment Information (Details)
 3 Months Ended 9 Months Ended
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Segment Information        
Number of reportable segment | segment     1  
Segment loss before income taxes        
Revenues, net $ 8,700 $ 1,505,322 $ (1,071,694) $ 1,505,322
Cost of revenues 16,965 439,815 195,918 439,815
Gross profit (8,265) 1,065,507 (1,267,612) 1,065,507
Research and development expenses        
Research and Development Expense, Total 3,251,099 7,134,706 11,385,971 21,201,875
Selling, general and administrative expenses        
Total selling, general and administrative expenses 7,550,845 9,679,481 25,667,565 29,610,692
Loss from operations $ (10,810,209) $ (15,748,680) $ (38,321,148) $ (49,747,060)
Segment Reporting, Other Segment Item, Composition, Description Other segment items included in segment loss include loss on equity method investment, interest income, interest expense, loss from change in fair value of promissory notes, warrant related expenses, warrant inducement expenses, and gain from change in fair value of warrant liability Other segment items included in segment loss include loss on equity method investment, interest income, interest expense, loss from change in fair value of promissory notes, warrant related expenses, warrant inducement expenses, and gain from change in fair value of warrant liability Other segment items included in segment loss include loss on equity method investment, interest income, interest expense, loss from change in fair value of promissory notes, warrant related expenses, warrant inducement expenses, and gain from change in fair value of warrant liability Other segment items included in segment loss include loss on equity method investment, interest income, interest expense, loss from change in fair value of promissory notes, warrant related expenses, warrant inducement expenses, and gain from change in fair value of warrant liability
Net loss before income taxes $ (20,319,272) $ (20,152,502) $ (47,830,487) $ (49,129,294)
Development and commercialization of ONS-5010/LYTENAVA        
Segment loss before income taxes        
Revenues, net 8,700 1,505,322 (1,071,694) 1,505,322
Cost of revenues 16,965 439,815 195,918 439,815
Gross profit (8,265) 1,065,507 (1,267,612) 1,065,507
Research and development expenses        
ONS-5010/LYTENAVA development 2,187,470 5,847,020 8,317,752 18,282,667
Compensation and related benefits 567,189 906,195 1,725,206 1,831,860
Stock-based compensation 63,266 91,636 254,202 289,889
Other research and development 433,174 289,855 1,088,811 797,459
Research and Development Expense, Total 3,251,099 7,134,706 11,385,971 21,201,875
Selling, general and administrative expenses        
Professional fees 1,173,827 1,315,395 4,667,134 5,120,664
Compensation and related benefits 1,520,593 1,943,321 4,101,809 5,806,232
Stock-based compensation 728,405 1,579,176 2,176,102 6,757,008
Europe commercial expenses 3,042,474 3,867,013 11,919,248 9,177,513
Facilities, fees and other related costs 1,085,546 974,576 2,803,272 2,749,275
Total selling, general and administrative expenses 7,550,845 9,679,481 25,667,565 29,610,692
Loss from operations (10,810,209) (15,748,680) (38,321,148) (49,747,060)
Other segment items (9,509,063) (4,403,822) (9,509,339) 617,766
Net loss before income taxes $ (20,319,272) $ (20,152,502) $ (47,830,487) $ (49,129,294)